Follow Greenville Nursing and Rehabilitation on Facebook! Click Here

To see a list of frequently asked questions please Click Here

Greenville | Nursing & Rehabilitation

Latest News

Latest News

Comparative Effectiveness of Moderna, Pfizer, and Janssen Vaccines in Preventing COVID-19 Hospitalizations

September 27, 2021

What We Know

Two 2-dose mRNA COVID-19 vaccines (from Pfizer-BioNTech and Moderna) and a 1-dose viral vector vaccine (from Janssen [Johnson & Johnson]) are currently used in the United states.

What is New

Among US adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11-August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%).

Implications for Public Health Practice

Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.

Two-dose regiments of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 hospitals during March-August 2021. VE against COVID-19 hospitalization for Moderna and Pfizer-BioNTech vaccines was 93% and 88%, respectively, whereas the single-dose Janssen vaccine had someone lower VE at 71%. Persons vaccinated with Janssen also had lower postvaccination anti-SARS-CoV-2 antibody levels than did recipients of mRNA vaccines. Although an immunologic correlate or protection has not been established for COVID-19 vaccines, antibody titers after infection and vaccination have been associated with protection (8). These real-world data suggests that the 2-dose Moderna and Pfizer-BioNTech mRNA vaccine regimens provide more protection than does the 1-dose Janssen viral vector vaccine regimen. Although the Janssen vaccine had lower observed VE, 1 dose of Janssen vaccine still reduced risk for COVID-19-associated hospitalization by 71%.

The findings in this report are subject to at least six limitations. First, this analysis did not consider children, immunocompromised adults, or VE against COVID-19 that did not result in hospitalization. Second, the Cis for the Janssen VE estimates were wide because of the relatively small number of patients who received this vaccine. Third, follow-up time was limited to approximately 29 weeks since receipt of full vaccination, and further surveillance of VE over time is warranted. Fourth, although VE estimates were adjusted for relevant potential confounders, residual confounding is possible. Fifth, product-specific VE by variant, including against Delta variants (B.1.617.2 and AY sublineages), was not evaluated. Finally, antibody levels were measured at only a single time point 2-6 weeks after vaccination and changes in antibody response over time as well as cell-mediated immune responses were not assessed.

To learn more, visit https://www.cdc.gov/mmwr/volumes/70/wr/mm7038e1.htm?s_cid=mm7038e1_x

Success Story: Brenda Clark

September 23, 2021

Brenda Clark came to us in June after experiencing a cerebrovascular accident (referred to commonly as a CVA or “stroke”) which left her weakened and unable to complete her daily activities independently. The stroke also effected her ability to communicate for a period of time. Both of these losses necessitated Brenda’s need for additional therapy after her hospital discharge.

Brenda admitted to Greenville Nursing and Rehabilitation and began a schedule of physical therapy, occupational therapy, and speech therapy to recover the strength, endurance, and abilities that she enjoyed prior to her event. Upon her arrival, Brenda was experiencing weakness in her legs which made her dependent on the assistance of staff to walk and transfer. She also required moderate assistance to complete her daily self-care routine. With her hard work and the knowledge and dedication of our therapy staff, Brenda is now able to get around on her own and able to have greater independence in her daily routine.

Brenda enjoys meal time, and says that her favorite dishes are our cheeseburger and fries and our fish. For activity, she mostly enjoys playing ball with the other residents during therapy. In her free time, you will find Brenda reading big, thick books or playing solitaire on her phone. She gets into animated features, and her favorite movie is “Despicable Me” with Gru and the Minions. We are so proud of the progress you’ve made, Brenda!

I’ve Already Had COVID-19. Do I Need the Vaccine?

September 17, 2021

You should get a COVID-19 vaccine, even if you have already had COVID-19. Research has not yet shown how long you are protected from getting COVID-19 again after you recover from COVID-19. COVID-19 vaccinations also help protect you even if you’ve already had the virus.


Evidence is emerging that people get better protection by being fully vaccinated compared with having COVID-19. One study showed that unvaccinated people who already had COVID-19 are more than two times as likely than fully vaccinated people to get COVID-19 again. Learn more about why getting vaccinated is a safer way to build protection than getting infected. If you were treated for COVID-19 with monoclonal antibodies or convalescent plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your healthcare professional if you are unsure what treatments you received or if you have more questions about getting a COVID-19 vaccine.


Experts are still learning more about how long vaccines protect against COVID-19 in real-world conditions. CDC will keep the public informed as new evidence becomes available. To learn more, visit https://www.cdc.gov/coronavirus/2019-ncov/vaccines/prepare-for-vaccination.html